 Released: Jul 1, 2008
Expires: Jul 1, 2009
Type: PDF
CVD affects approximately 80 million Americans and is responsible for roughly one third of US mortality, with nearly 2400 CVD-associated deaths occurring each day—more than cancer, chronic lower respiratory diseases, accidents, and diabetes mellitus combined 1. CVD is associated with an estimated total annual cost of $400 billion. Among the identified modifiable...
|
- CME Credits/Hours: 1.00
- CPE Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
Released: Feb 28, 2008
Expires: Feb 28, 2009
Type: Video
This presentation aims to focus on current strategies to optimize oral antiplatelet agents in the treatment of ACS and PCI. Topics addressed include current limitations with clopidogrel, variability in response to clopidogrel and the clinical outcomes associated with poor response, and strategies to reduce variability. Finally, a comparison of the biologic response of prasugrel and...
|
- CME Credits/Hours: 0.50
- Cost: Free
-
System Requirements:
|
Released: Feb 28, 2008
Expires: Feb 28, 2009
Type: Video
This presentation focuses on the results of the TRITON-TIMI 38 trial, which examines the use of the investigational thienopyridine prasugrel compared to clopidogrel in patients with ACS who were undergoing primary PCI. Highlighted data from the trial is presented, including several in-depth analyses investigating sub-populations as it relates to ischemic endpoints as well as...
|
- CME Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
Released: Feb 28, 2008
Expires: Feb 28, 2009
Type: Video
This presentation aims to address the central role of platelets in acute coronary syndromes (ACS) and the use of both oral antiplatelet therapy and interventional therapy as cornerstones for the treatment of ACS. Topics to be discussed include the pharmacology of approved and investigational oral antiplatelet agents, clinical trial data detailing the use of...
|
- CME Credits/Hours: 0.50
- Cost: Free
-
System Requirements:
|
Released: Feb 19, 2008
Expires: Feb 19, 2009
Type: Video
Biologic agents that block TNF have proven highly effective in improving the signs and symptoms of rheumatoid arthritis (RA), preventing the progression of joint damage, and improving functional status and quality of life. The introduction of TNF inhibitors has helped elevate the goals of treating RA, such that low disease activity or even remission are commonly considered...
|
- CME Credits/Hours: 0.50
- CPE Credits/Hours: 0.50
- CNE Credits/Hours: 0.50
- Cost: Free
-
System Requirements:
|
Released: Nov 30, 2007
Expires: Nov 30, 2008
Type: PDF
Acute coronary syndrome (ACS) is a broad term that has evolved to represent a spectrum of diseases from unstable angina (UA) to myocardial infarction (MI) with or without ST-segment elevation (STEMI or NSTEMI, respectively). While these conditions have very different presentations and are associated with differing levels of risk, they appear to share a common pathophysiologic...
|
- CME Credits/Hours: 1.00
- CNE Credits/Hours: 1.00
- CPE Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
Released: Nov 20, 2007
Expires: Nov 30, 2008
Type: PDF
Stroke is a major problem in the United States, with approximately 700,000 individuals experiencing new or recurrent stroke each year. Stroke prevention primarily involves risk factor reduction via lifestyle modifications and often drug therapy to reduce the impact of hypertension, diabetes, dyslipidemia and smoking. The need for safe and effective agents to prevent stroke is...
|
- CME Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
Released: Nov 7, 2007
Expires: Nov 7, 2008
Type: Video
Many therapies currently exist today for the treatment of hypertension, however, there still remains a critical need to better establish and define the concept of vascular protection. To appreciate this concept, it is important to understand the data which results in a reduction in the risk of cardiovascular outcomes (MI, stroke or death) associated with some treatment regimens....
|
- CME Credits/Hours: 0.75
- Cost: Free
-
System Requirements:
|
Released: Oct 1, 2007
Expires: Oct 31, 2008
Type: PDF
End-stage renal disease (ESRD) requiring renal replacement therapy or kidney transplantation is the final consequence of chronic kidney disease (CKD). CKD has emerged as an important public health concern with the recognition of the dramatic association of CKD and cardiovascular disease (CVD). Among patients with early CKD, the risk of death (likely from CVD) is much greater than...
|
- CME Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
Released: Sep 12, 2007
Expires: Sep 12, 2008
Type: PDF
Mortality data continues to show that cardiovascular (CV) is responsible for approximately 36% of deaths in the United States. Coronary heart disease causes 1 out of every 5 deaths. In 2007, an estimated 700,000 Americans will have a new coronary attack and an additional 500,000 will have a recurrent attack. Although in-hospital mortality from acute myocardial...
|
- CME Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
|
